ADAR1 Capital Management’s Protara Therapeutics TARA Stock Holding History

ADAR1 Capital Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.9M	Sell	940,512 -196,287	-17%	-$1.16M	0.29%	77
2025 Q4	$6.06M	Buy	1,136,799 +1,101,576	+3,127%	+$6.12M	0.45%	50
2025 Q3	$153K	Sell	35,223 -87,467	-71%	-$283K	0.01%	189
2025 Q2	$372K	Hold	122,690	–	–	0.06%	129
2025 Q1	$523K	Hold	122,690	–	–	0.1%	101
2024 Q4	$648K	Buy	+122,690	New	+$396K	0.13%	103
2024 Q2	–	Sell	-2,000	Closed	-$8.02K	–	313
2024 Q1	$8.02K	Sell	2,000 -194	-9%	-$626	﹤0.01%	233
2023 Q4	$4.11K	Buy	+2,194	New	+$3.23K	﹤0.01%	151

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

ADAR1 Capital Management's TARA Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Protara Therapeutics (TARA) stake by 17% in Q1 2026, selling an estimated $1.16M and leaving 940,512 shares worth $4.9M. The position accounts for 0.29% of the portfolio, ranked #77.

ADAR1 Capital Management first reported a position in TARA in Q4 2023 and has held it in 8 quarters since. The position peaked at $6.06M in Q4 2025. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

ADAR1 Capital Management held 940,512 shares of Protara Therapeutics worth $4.9M as of Q1 2026.
ADAR1 Capital Management sold 196,287 Protara Therapeutics shares in Q1 2026, an estimated $1.16M.
Protara Therapeutics made up 0.29% of ADAR1 Capital Management's portfolio in Q1 2026, its #77 holding.
ADAR1 Capital Management first reported a position in Protara Therapeutics in Q4 2023 and has held it in 8 quarters since.
ADAR1 Capital Management's Protara Therapeutics position peaked at $6.06M in Q4 2025.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.